Evaluating the Clinical Impact of Ureteral Frozen Section Analysis During Radical Cystectomy: A Single-Center Retrospective Study Authors: Saleh Al-Gburi, Magi Williams, Ketan Agarwal, Thiagarajan Nambirajan Published: 2024 ABSTRACT IntroductionThe objective of this study is to find out if there are any differences in upper urinary tract recurrence and overall mortality between patients who underwent a frozen section analysis during radical cystectomy and those who did not.Materials and methodsIn an observational retrospective cohort study, we evaluated data from 164 patients who underwent radical cystectomy in our institution over a five-year period from 2013 to 2018. Fisher's exact test was applied to find any difference in upper urinary tract recurrence between the two groups. The Kaplan-Meier method and the log-rank (Mantel-Cox) test were used to determine differences or equivalence between treatment groups.ResultsThe sensitivity was 84.6% and the specificity was 95.3% for the frozen section. There was no statistically significant relationship between performing a frozen section and upper urinary tract recurrence, as indicated by Fisher's exact test (p=0.619). The Kaplan-Meier test showed no statistically significant relationship between performing a frozen section analysis and overall mortality.DiscussionThe use of ureteric frozen section analysis during radical cystectomy is traditionally taught during surgical training, but the evidence base for this practice is sketchy. Frozen section analysis is thought to reduce the chances of local recurrence and arguably upper urinary tract recurrence. The overall upper urinary tract recurrence after radical cystectomy is reported to be 2-6%, consistent with the 3.3% observed in our study.ConclusionOur study demonstrates that while frozen section analysis is sensitive and specific in detecting dysplasia, it does not significantly impact upper tract recurrence or overall mortality. Introduction Radical cystectomy (RC) has been the gold standard for muscle-invasive urothelial cancer of the bladder as well as non-muscle-invasive urothelial cancer, with a high risk of progression or that is non-responsive to intra-vesical immunotherapy: Bacillus Calmette-Guérin (BCG) [1]. Muscle-invasive bladder cancer is defined as a tumor that invades the bladder's muscularis propria layer (T2) for which RC combined with urine diversion has been the gold standard treatment for decades [2]. Upper urinary tract recurrence (UUTR) following RC is in the order of 2-8.7% [3,4]. Conventionally, urologists are trained to do frozen section analysis (FSA) at the time of RC to ensure the ureteric margins are clear of cancer. This is thought to reduce the chances of local recurrence and arguably UUTR. The objective of this study is to find out if there are any differences in UUTR and overall mortality between patients who underwent FSA during RC and those who did not. Materials and methods In an observational retrospective cohort study, we evaluated data from 164 patients who underwent RC in our institution over a five-year period from 2013 to 2018. Basic demographic, clinical, pathological, perioperative, and oncological features were collected retrospectively. The patients underwent open procedures in the early part of the study, and the robotic-assisted laparoscopic approach was introduced in 2015. A full histological examination using hematoxylin and eosin (H&E) stains in permanent sections was performed following FSA. We compared those who had intra-operative FSA of the ureters and those who did not. The sensitivity (SN) and specificity (SP) of FSA were calculated. Twenty-five patients were excluded as follow-up information was not available. Additionally, 20 patients with a follow-up period of less than 10 months were also excluded from the study due to reasons such as missing records or death from intercurrent illness not related to cancer. The final study cohort comprised 119 patients. The follow-up assessment included comprehensive medical history, physical examination, and laboratory tests, including full blood count, liver and kidney function tests, urine microscopy, and urine cytology. Computed tomography (CT) scans of the chest, abdomen, and pelvis, with or without the urographic phase, were also performed on these patients depending on the renal function and history of allergy to contrast agents. The follow-up protocol involved appointments every six months for the first two years, followed by annual visits. Categorical data is presented as frequencies and percentages, while continuous variables are presented as means with standard deviations or medians. Univariate analysis was conducted as follows: continuous variables were compared using either a t-test or a Mann-Whitney test, depending on whether the data were normally or non-normally distributed, respectively. Categorical variables were compared using either Fisher's exact test or the chi-squared test, depending on the specific conditions. The Shapiro-Wilk test was used to assess data normality. Survival curves were generated for each patient group using the Kaplan-Meier method, and the log-rank (Mantel-Cox) test was used to determine differences or equivalence between treatment groups. Patients who did not experience the event were censored at their last follow-up date. Statistical significance was set at p<0.05. All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25.0 (Released 2017; IBM Corp., Armonk, New York, United States). Results The total number of patients was 164, of which 78 patients had intra-operative FSA of the ureters, while 86 did not. The definition of true positive is that for those patients who had positive FSA that was confirmed on H&E stain examination, false positive is those patients who had positive FSA that was disproved on H&E stain examination, true negative is those patients who had negative FSA that was confirmed on H&E stain examination, and false negative is those patients who had positive FSA that was disproved on H&E stain examination. The SN was 84.6% and the SP was 95.3% for FSA as illustrated in Table 1. Table 1The sensitivity and specificity of the frozen section H&E: hematoxylin and eosin; TP: true positive; FN: false negative; FP: false positive; TN: true negative Positive on permanent section (paraffin/H&E) (13)Negative on permanent section (paraffin/H&E) (65)Positive frozen section (15)TP (11)FP (3)Negative frozen section (63)FN (2)TN (62)SN=(TP/TP+FN)×100=84.6%, SP=(TN/TN+FP)×100=95.3% The sensitivity and specificity of the frozen section H&E: hematoxylin and eosin; TP: true positive; FN: false negative; FP: false positive; TN: true negative Table 2 illustrates the preoperative demographics and clinic characteristics of the patients who underwent RC after exclusion. Table 2Preoperative demographics and clinic characteristics ASA: American Society of Anesthesiologists; FSA: frozen section analysis FSA (61)Without FSA (58)P-valueGender Male (%)51(84%)35 (60.3%) Female (%)10 (16%)23 (39.7%) Preoperative creatinine83 (SD 33)84 (SD 46)0.744ASA 1 (%)8 (13.1%)9 (15.5%) ASA 2 (%)46 (77.4%)29 (50%)ASA 3 (%)7 (11.5%)20 (34.5%)Pre-op chemotherapyYes12 (19.7%)12 (20.7%)0.535No49 (80.3%)46 (79.3) Salvage cystectomy4 (6.6%)2 (3.4%)0.154Open (%)59 (97%) 41 (70.7%)0.001Robotic surgery (%)2 (3%)17 (29.3) Preoperative demographics and clinic characteristics ASA: American Society of Anesthesiologists; FSA: frozen section analysis The cancer's pathological features are shown in Table 3. Table 3Pathological features T0: no evidence of a primary tumor in the bladder; Ta: non-invasive papillary carcinoma Frozen sectionNo frozen sectionP-valueT0 (%)13 (21.3%)5 (8.6%)0.167Ta (%)4 (6.6%)2 (3.4%)CIS (%)6 (9.8%)8 (13.7%)T1 (%)13 (21.3%)5 (8.6%)T2 (%)7 (11.5%)11(18.9%)T3a (%)6 (9.8%)11 (18.9%)T3b (%)8 (13.1%)14 (24.1%)T4 (%)4 (6.6%)2 (3.4%)N0 (%)54 (88.5%)46 (84.5%)0.232N1 (%)6 (9.8%)6 (10.3%)N2 (%)1 (1.6%)3 (5.2%)R1 (%)5 (8.2%)6 (10.3%)0.154Squamous differentiation5 (8.2%)4 (6.9%) Pathological features T0: no evidence of a primary tumor in the bladder; Ta: non-invasive papillary carcinoma We evaluated UUTR in these patients after a median follow-up period of 69 months with a minimum duration of 10 months and a maximum duration of 124 months. The recurrence rates are presented in Table 4. Table 4UUTRFSA: frozen section analysis; UUTR: upper urinary tract recurrence FSA (61)Without FSA (58)UUTR3 (4%)1 (1.7%) UUTR FSA: frozen section analysis; UUTR: upper urinary tract recurrence Among the three patients with UUTR who underwent FSA, one required three FSA before achieving a negative margin, indicating multifocal disease. The other two patients were negative on both FSA and final histological examination. Only one patient without FSA had UUTR but was found to have carcinoma in situ (CIS) in the ureter on final histology. There was no statistically significant relationship between performing an FSA and UUTR, as indicated by Fisher's exact test (p=0.619). Regarding the cases with UUTR, two had a T3b stage, one had a T4 stage, and one had CIS on the final histological examination. Additionally, two cases were classified as N1, while the other two were N0. The overall mortality rate was 45 patients (37.8%) over a 35-month period. The Kaplan-Meier test was used to evaluate any differences in survival over time in relation to performing an FSA. The analysis showed no statistically significant relationship between performing an FSA and overall mortality, with a log-rank (Mantel-Cox) value of 0.651, as shown in Figure 1. The Kaplan-Meier test Discussion The use of ureteric FSA during RC is traditionally taught during surgical training, but the evidence base for this practice is unclear. FSA is thought to reduce the chances of local recurrence and arguably UUTR. The overall UUTR after RC is reported to be 2-6%, consistent with the 3.3% observed in our study [5,6]. Systematic reviews have suggested that UUTR occurs in 4-10% of RC and is associated with poor prognosis and late diagnosis [7]. According to a meta-analysis, patients with non-muscle-invasive bladder cancer are twice as likely to develop UUTR compared to those with invasive disease [8]. Follow-up investigations identified UUTR in 38% of patients, while symptoms led to the diagnosis in 62%. In the current study, all UUTRs were diagnosed by interval imaging. Some studies advocate FSA routinely during RC, while others do not. Soliman et al. suggested that routine FSA should not be disregarded to achieve tumor-free uretero-enteric anastomosis and reduce the incidence of UUTR [9]. On the other hand, Tang et al. found that even though the ureter was resected until a negative margin was reached, patients with positive ureteric FSA after cystectomy had an increased risk of overall mortality, leading them to suggest omitting FSA during RC for non-muscle-invasive bladder cancer [10]. Mukha et al. noted that ureteral resection to achieve a negative margin on FSA did not appear to prevent upper tract recurrence and concluded that routine FSA may not be necessary for most patients undergoing RC [11]. Similarly, Schumacher et al. stated that if the ureters were resected at the point where they cross the common iliac vessels, ureteric FSA would be unnecessary [12]. The current study did not show any differences in the risk of UUTR between the two cohorts. This led to a change in our practice in our institution to omit routine FSA and resect the ureters at the level of the common iliac artery during RC. We did not find any association between UUTR and non-muscle-invasive bladder cancer, but the number in this study is too small to draw a meaningful conclusion. No significant factors for UUTR were identified by Rabbani et al. [13]. In our study, however, UUTR occurred in patients with advanced T-stage and lymph node metastasis. It has also been suggested that individuals with intramural or juxtavesical ureter carcinoma involvement or bladder CIS may be at higher risk for UUTR [14,15]. Given that our study found no difference in overall mortality or UUTR between patients who did and did not undergo FSA, it suggests that performing a frozen section until a negative margin is achieved may not impact outcomes and is not recommended. In our study, the SN and SP of FSA were 84% and 95%, respectively. While the SP aligns with findings from other studies, the SN varies widely across different studies [16,17]. Comparable to previous studies such as Perri et al., who found a 53% mortality rate in 24 months for RC, our study revealed an overall mortality rate of 45 patients (37.8%) over a 35-month period [18]. Kwiatkowska et al. reported that five-year overall survival is expected to be between 50% and 80% based on extensive examination of outcomes following RC [19]. The limitations of our study include its retrospective design, single-center setting, and relatively small sample size compared to other studies. However, one of the strengths of our study is the median follow-up period of 69 months. Multicenter studies or systematic reviews of recent literature are strongly advised as they will provide more reliable information. Conclusions Although FSA is sensitive and specific in detecting dysplasia, our data shows that there was no difference in UUTR or mortality between the patients who had FSA and those who did not. Even yet, our study has limitations, as previously mentioned. Future multicenter studies and systemic reviews will be helpful in providing a more definitive conclusion about this topic.